Using novel point-of-care diagnostic tests and mathematical modelling to achieve hepatitis B elimination: The Rapid B Study

使用新型即时诊断测试和数学模型来消除乙型肝炎：快速乙型肝炎研究

• 批准号: nhmrc : 2002268
• 金额: $ 38.19万
• 依托单位国家: 澳大利亚
• 项目类别: Ideas Grants
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/using-novel-point-b-study/1779882
• 关键词: Using; novel; point; care; diagnostic

Liver cancer is increasing rapidly in Australia and globally and depite hepatitis B virus infection being the leading cause, treatment rates are low. We have developed innovative point-of-care blood tests that use a single droplet of blood to measure liver damage, that will help overcome barriers to treatment uptake worldwide. The Rapid B Study will use mathematical modelling to investigate the most cost-effective way to combine these novel tests with treatment to reduce liver cancer deaths.

肝癌在澳大利亚和全球范围内迅速增加，并且由于B型肝炎病毒感染是主要原因，治疗率很低。我们开发了创新的即时血液检测，使用一滴血来测量肝损伤，这将有助于克服全球治疗吸收的障碍。Rapid B研究将使用数学模型来研究将这些新的测试与治疗相结合以减少肝癌死亡的最具成本效益的方法。